Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

Compounded semaglutide has emerged as a significant development in the management of obesity and type 2 diabetes. As a ...

In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.

Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...

Semaglutide injections effectively support weight loss by regulating appetite and glucose levels, offering benefits for ...

Grappling with obesity and the metabolic diseases cascading from it, they are now among the plurality of Americans who have ...

A SELECT trial subanalysis showed that semaglutide works as well in people with CVD, overweight/obesity, and impaired kidney ...

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular ...

Representational Photo The exploration of novel peptides for their potential impact on metabolic pathways has been a ...

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, ...

The House and Senate are racing to complete the government funding process with the Sept. 30 shutdown deadline looming and lawmakers eager to head back to their districts to campaign ahead of the ...

A new study, led by Professor John Deanfield from University College London (UCL), reveals that the anti-obesity medication ...